Increased Shareholder Value

Increased Shareholder Value by Enhancing Intellectual Property

The intellectual property strategy developed by ConjuChem has two primary objectives. First, the Company is continually augmenting its patent portfolio with new patent submissions to strengthen its patent core portfolio of Drug Affinity Complex (DAC™) and Preformed Conjugate-Drug Affinity Complex (PC-DAC™) technology platforms. Second, the Company seeks new patent protection for each of its new constructs or classes of constructs it develops. This construct protection includes claims for composition of matter (compound structure), method of use, and manufacturing processes. This is in contrast to the more limited patent claims normally possible when applying most drug delivery technologies to existing compounds.

The Company believes its current core patents in Canada, the United States, Europe, and other parts of the world prevent another firm from marketing a drug product using in vivo or in vitro bioconjugation to cysteine 34 with albumin or any highly similar technology without infringing on one or more of its patents.

Though the therapeutic activities of DAC™ and PC-DAC™ complexes are consistent with those of the drug compounds from which they were derived, the other properties of these constructs—such as duration of activity and safety profile—are substantially different from those of the original drug compounds. ConjuChem believes the DAC™ and PC-DAC™ constructs it creates will be considered unique and non-obvious, thus enabling them to receive new composition of matter patent protection.